Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms
Fig 5
Variant call concordance study between the 48-gene panel for myeloid neoplasms and 35-gene panel for hematologic neoplasms.
(A) Number and type of variants compared per gene. (B) Scatter plot of VAFs (n = 1,094) across 141 trials detected by the 48-gene panel (x-axis) and 35-gene panel (y-axis).